A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

Inclusion Criteria:

• Participant must be ≥18 to ≤89 years of age, at the time of signing the informedconsent

• Confirmed diagnosis of MOG-AD consistent with published diagnostic criteria forMOG-AD

• Participant has history of relapsing MOG-AD with at least 1 documented relapse overthe last 12 months and a documented positive serum MOG Ab test using a cell-basedassay (CBA) within 6 months prior to randomization

• Participant must be clinically stable at the time of the Screening Visit and duringthe Screening Period

Exclusion Criteria:

• Participant has been diagnosed with a neurological autoimmune disease (includingmultiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrumdisorder (NMOSD)), or a systemic autoimmune disease that in the opinion of theinvestigator can interfere with the safety of the participant

• Participant has a clinically important active infection (including unresolved or notadequately treated infection) as assessed by the investigator, includingparticipants with a serious infection within 6 weeks prior to the first dose of theinvestigational medicinal product (IMP)

• Participant has a current or medical history of primary immunodeficiency

• Participant tests positive for aquaporin-4 antibodies at Screening

• Participant has a serum total IgG level ≤ 5.5g/L